GlycoVaxyn is a clinical stage biopharmaceutical company focused on the development and manufacture of next-generation bioconjugate vaccines utilizing its proprietary recombinant DNA technology.



 
21.01.15 Promising Phase I interim data for ExPEC vaccine program triggers first milestone payment in clinical co-development with Janssen
11.09.14 GlycoVaxyn AG to Present at the 25th Joint Glycobiology Meeting in Gent, Belgium
07.08.14 GlycoVaxyn AG to Present at the 248th ACS National Meeting & Exposition in San Francisco, USA
 

GlycoVaxyn will be present during:

- Joint Meeting of the Society for Glycobiology in Honolulu on November 16-19, 2014

- 25th Joint Glycobiology Meeting in Gent on September 14-16, 2014

- The 6th Baltic Meeting on Microbial Carbohydrates in Gdansk on September 7-10, 2014